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Abstract
Recent translational research developments in Spinal Muscular Atrophy (SMA), outcome
measure design and demands from regulatory authorities require that clinical outcome
assessments are ‘fit for purpose’. An international collaboration (SMA REACH UK, Italian
SMA Network and PNCRN USA) undertook an iterative process to address discontinuity in
the recorded performance of the Hammersmith Functional Motor Scale Expanded and
developed a revised functional scale using Rasch analysis, traditional psychometric tech-
niques and the application of clinical sensibility via expert panels. Specifically, we intended
to develop a psychometrically and clinically robust functional clinician rated outcome mea-
sure to assess physical abilities in weak SMA type 2 through to strong ambulant SMA type 3
patients. The final scale, the Revised Hammersmith Scale (RHS) for SMA, consisting of 36
items and two timed tests, was piloted in 138 patients with type 2 and 3 SMA in an observa-
tional cross-sectional multi-centre study across the three national networks. Rasch analysis
demonstrated very good fit of all 36 items to the construct of motor performance, good reli-
ability with a high Person Separation Index PSI 0.98, logical and hierarchical scoring in 27/
36 items and excellent targeting with minimal ceiling. The RHS differentiated between clini-
cally different groups: SMA type, World Health Organisation (WHO) categories, ambulatory
status, and SMA type combined with ambulatory status (all p < 0.001). Construct and con-
current validity was also confirmed with a strong significant positive correlation with the
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WHO motor milestones rs = 0.860, p < 0.001. We conclude that the RHS is a psychometri-
cally sound and versatile clinical outcome assessment to test the broad range of physical
abilities of patients with type 2 and 3 SMA. Further longitudinal testing of the scale with
regards change in scores over 6 and 12 months are required prior to its adoption in clinical
trials.
Introduction
Spinal Muscular Atrophy (SMA) is the most common disease of the spinal motor neuron
occurring in 1 in 6–10,000 births with a carrier frequency of 1 in 35–70 [1–5]. SMA is an auto-
somal recessive condition due in most cases to the homozygous deletion of the SMN1 gene [2,
4–7]. There are four types of SMN1-related SMA, with types 1, 2 and 3 manifesting during
infancy/childhood, while the type 4 onset is in adulthood [7]. Classification of SMA type
depends upon the age of onset and highest level of motor function achieved [5–7]. Our study
is focused on the SMA type 2 and 3 phenotype where the highest level of functional ability
achieved is independent sitting in SMA 2, and standing or walking in SMA 3 [7].
With greater understanding of the molecular genetics of SMA over the past two decades,
therapeutic interventions for this condition are rapidly entering phase 2 and 3 clinical trials [4,
8]. Evidence of efficacy of such therapeutics involves thorough assessment of the participant’s
physical abilities through the use of functional scales [1, 7, 8]. Functional scales have been cited
as important and recommended as primary outcome measures in clinical trials for the detec-
tion of meaningful changes and inclusion/exclusion criteria [9].
There has been much activity in the last fourteen years to develop a clinical outcome assess-
ment to assess gross motor function in SMA types 2 and 3. The first SMA specific outcome
measure, the Hammersmith Functional Motor Scale (HFMS), was developed in 2003 as both a
clinical and research tool [10]. The HFMS is an assessment of the physical abilities of SMA
type 2 and type 3 patients with limited ambulation. It is an ordinal scale consisting of twenty
items with individual item scoring as 2 for unaided, 1 for performed with modification or
adaption and 0 for unable [10]. The HFMS was widely adopted by the SMA community, how-
ever some revisions were implemented by several groups to improve its measurement capabili-
ties. To remove any confounding effect of fatigue and effect of positional changes, the order of
the HFMS was modified (MHFMS) [11, 12]. To enable its use in the ambulant type 3 popula-
tion the HFMS was expanded to include 13 items from the Gross Motor Function Measure to
form the Hammersmith Functional Motor Scale Expanded (HFMSE) [13]. Although not for-
mally reported in the literature, the MHFMS was extended to include 8 additional gross motor
items and timed tests resulting in the Modified Hammersmith Functional Motor Scale
Extended (MHFMS-EXTEND) [14].
As an SMA specific outcome measure, the HFMSE is widely used internationally in clinical
practice, in clinical trials and to document SMA natural history and trajectories of disease
course [15–18]. The reliability, validity and sensitivity of change of the HFMSE was discussed
at a recent international workshop on SMA outcome measures and the scale was found to fulfil
the majority of criteria required by regulatory authorities [9]. Furthermore, the HFMSE is cor-
related with other aspects of SMA disease severity with positive associations found with SMN2
copy number, compound muscle action potential (CMAP), forced vital capacity (FVC) and
muscle strength, making it clearly a disease-specific outcome measure of choice for clinical tri-
als [3, 19, 20].
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While the HFMSE captures clinically relevant aspects of disease progression, some limita-
tions with regards psychometric properties have been suggested [21, 22]. Rasch analysis has
identified some discontinuities in its measurement properties and highlighted some issues
with validity regarding measuring motor performance in different SMA phenotypes [21]. This
background gave us the impetus to better define and assess the feasibility to further improve
the well-established HFMSE and expand its utility and strength in both the clinical and scien-
tific setting. Using the HFMSE as a foundation, this study aimed to develop a psychometrically
and clinically robust functional clinician rated outcome measure to assess the spectrum of
physical abilities from weak non-ambulant to strong ambulant patients with SMA types 2
and 3.
Methods
Construction & development of the Revised Hammersmith Scale for
SMA (RHS)
Intent of scale—Concept of interest and context of use. An international multidisciplin-
ary expert panel of Physiotherapists and Clinicians representing three established national net-
works, SMA REACH UK, the Italian SMA Network and the Paediatric Neuromuscular
Clinical Research (PNCR) SMA Network USA, attended several in-depth workshops and tele-
conferences to revise the HFMSE (Fig 1). The intent was to develop a scale to assess the spec-
trum of gross motor function from weak individuals with type 2 SMA, who may have lost the
ability to sit, through to strong ambulant individuals with type 3 SMA. The method of scale
development followed recommendations by the United States Food and Drug Administration
(FDA) for outcome measures [23]. Efforts were also made to ensure scale development met
the criteria of the Consensus-based Standards for the selection of health status Measurement
Instruments (COSMIN) checklist and in anticipation of the International Society for Pharma-
coeconomics and Outcomes Research recommendations for good practice [24, 25].
At the time of revising the scale, priority was given to maintaining the original construct of
the scale which has proved to be an excellent tool to monitor natural history and detect
changes following clinical interventions [18, 26]. The use of Rasch methodology throughout
the process cemented the intent for the scale to be more psychometrically robust. The expert
panel was employed to ensure that the content and scoring of the scale, in addition to being
psychometrically robust, was also relevant and applicable for use in everyday clinical practice
to ensure it remained a scale with high clinical utility. The application of the scale was consid-
ered primarily an evaluative tool, however it was acknowledged it may have further potential
to be both a discriminative and predictive tool, particularly with regards scale linearisation in
the future. As with the original scales the need to remain aligned to the underpinning con-
struct and use of minimal equipment was paramount.
Underpinning construct. The theoretical construct underpinning both the original and
the revised scale was the natural history and pattern of weakness seen in SMA type 2 and 3 and
its presentation during gross motor and functional activities. The scale was based upon a
reflective conceptual model of motor performance in SMA. The intent was for the scale to
reflect the development of functional mobility skills and include progressively more challeng-
ing activities, to ensure capacity for improvement could be demonstrated. The construct of
interest is associated with the activity domain of the International Classification of Function-
ing, Disability and Health framework [27].
Clinical content validity—Definition of items. All 33 items of the HFMSE were dis-
cussed by the international expert panel regarding their individual clinical relevance in assess-
ing physical abilities in SMA, their scoring criteria, psychometric properties and experience of
Revised Hammersmith Scale for spinal muscular atrophy
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use in clinical trials. The opportunity to expand the scale to a higher level of functional ability
was also explored. Scoring criteria for each item was agreed to ensure each grade for the item
represented a distinctly different change in function/ability; the application of modern psycho-
metrics, Rasch analysis, aided this process. Commonly used compensations movements
observed in SMA, in addition to the ability to achieve functional activities with/without
Fig 1. Revised Hammersmith Scale for Spinal Muscular Atrophy: Process of development. Iterative
process of RHS development—expert panel, SMA outcome measure review, draft instrument, scale pilot and
subsequent modification summarised for draft version 1, 2 and final version of the RHS.
doi:10.1371/journal.pone.0172346.g001
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compensations were discussed, and the ability to functionally achieve the item remained para-
mount. To distinguish between the more functionally able patients and to generate a scale with
items charting the capacity to improve, the most difficult scoring criteria was often chosen as a
grade which represented the abilities expected of the typically developing population. Where
appropriate, experts drew on their clinical experience of functional scales used in SMA to
reduce floor and ceiling effects, for example the Children’s Hospital of Philadelphia Infant Test
of Neuromuscular Disorders (CHOP INTEND) and North Star Ambulatory Assessment
(NSAA), to ensure the most relevant items for the target population were represented [28, 29].
The CHOP INTEND is a scale specifically designed to assess extremely weak infants with
SMA type 1 [29]. The NSAA was originally developed as an outcome measure for the assess-
ment of functional abilities in ambulant Duchenne Muscular Dystrophy and despite not hav-
ing been formally validated for SMA, it has been shown to be a clinically relevant tool in the
evaluation of ambulant SMA 3 patients [28, 30, 31].
Each expert panel workshop resulted in revisions to the scale, and the resultant scales were
pilot tested in the international cohorts (Fig 1). In this paper we present the final version of the
RHS. A manual of RHS testing procedures, detailed scoring criteria and testing proforma were
produced in English for the UK and USA networks; these were then translated into Italian for
the Italian Network by the Lead Italian Physiotherapist.
Psychometric properties—Rasch analysis. The HFMS and subsequent modifications
were developed using classical test theory. It has been argued that scale development using tra-
ditional psychometric methods, due to their focus at the scale/test level, has limitations due to
the inability to differentiate person ability and item difficulty, and such techniques provide a
more gross estimate of reliability and standard error of measurement [32, 33]. Modern test
theory, specifically latent trait theory (LTT), is widely advocated as a more detailed/sensitive
and robust analytical approach to the assessment and development of improved health out-
come measures [32–35].
Latent trait theories focus at the individual item and person level by addressing the rela-
tionship between the measurement and probability of their response occurring [35]. The
modern psychometric technique (latent trait theory) employed in this study was the Rasch
Unidimensional Measurement Model (unrestricted and simple logistic model); it uses five
key tests of scale validity and reliability by addressing individual item fit and internal order-
ing within items, targeting, dependency, reliability and stability [21, 35, 36]. The method of
estimation used was pairwise estimation for polytomous Rasch models [37]. The Rasch
method is a robust approach and explores in detail why the data may not fit the mathematical
model by testing both the stability of people and the instrument. It also allows rigorous test-
ing of the construct of interest and thus employs theory-referenced measurement [35]. Rasch
analysis was conducted using Rumm2030 software [38] to assess the psychometric properties
of the two draft scales and the finalised RHS scale, this paper reports upon the final pilot of
the RHS. Results from pilot testing earlier drafts informed re-design of the scale at each work-
shop/teleconference.
Additional statistical analysis. Descriptive statistics of median and interquartile range
(IQR) were used to describe patient demographics. Discriminative and groups validity was
assessed for ambulatory status, SMA type, SMA type and current ambulatory status combined,
scoliosis surgery and highest current level of ability as assessed with the World Health Organi-
sation (WHO) motor milestones [39]. If a participant achieved a score of 0 for the WHO
motor milestones they were classified as unable to sit independently. The relationship with age
was further analysed according to the stratification groups proposed by Mercuri et al., 2016
[18];< 5 years, 5–14.9 years and 15 years. Groups and discriminant validity were assessed
Revised Hammersmith Scale for spinal muscular atrophy
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using the Kruskal Wallis and Mann-Whitney U tests, p< 0.05 was deemed significant and
p 0.001 highly significant.
To test the construct of measuring progressively more difficult motor function ability, con-
current validity was assessed comparing the RHS with the WHO motor milestones using
Spearman’s rho correlation [39]. Strength of correlations were quantified as moderate when
rs = 0.50 to 0.69, strong when rs = 0.70 to 0.89 and very strong when rs = 0.90 to 1.00. All addi-
tional analysis was conducted using IBM SPSS Statistics version 22 [40].
An enhanced utility of the RHS in the ambulant type 3 populations is the incorporation of
two timed tests in item 19 –run/walk 10 metres and item 25 –rise from floor. A timed test
subgroup analysis was conducted in type 3 ambulatory patients. Due to the relatively small
subpopulation non-parametric tests were conducted and median and IQR presented, the rela-
tionship between age and total RHS score were investigated in addition to discriminative valid-
ity regarding ordinal scoring within the items.
Pilot testing the Revised Hammersmith Scale for SMA. The international consortium
piloting the RHS consisted of three national networks comprising seven sites: SMA REACH
UK—London and Newcastle, Italian SMA Network—Rome and the PNCR Network for SMA
USA—Columbia, Philadelphia, Boston, and Stanford. Two draft revised scales were piloted
prior to the final version: version 1 January—May 2014 (n = 52), and version 2 June to Decem-
ber 2014 (n = 70). Following each pilot the scale content, definition of items and scoring were
re-analysed according to clinical meaningfulness and Rasch analysis and repeated until agree-
ment was achieved on the final scale, the Revised Hammersmith Scale for SMA (RHS), in
March 2015, Fig 1.
The final version of the RHS was piloted March to September 2015 alongside the WHO
motor milestones. The WHO motor milestones are six clearly defined gross motor milestones
recognised by WHO as essential to achieving independent ambulation [39]. The items assess
sitting without support, hands and knees crawling, standing with assistance, walking with
assistance, standing alone and walking alone. Completed alongside the RHS the WHO items
were often more difficult than the equivalent RHS item. For example the RHS definition of
independent sitting requires the individual to sit for a count of three compared to the WHO
definition where sitting is maintained for ten seconds.
The participants assessed with the RHS were enrolled in network specific natural history
studies which all had local ethical approvals in place permitting the pilot of functional scales
(SMA REACH UK: National Research Ethics Committee (REC) London Bromley, Health
Research Authority REC reference 13/LO/1748; PNCR USA Institutional Review Boards (IRB)
and Numbers: Columbia University Medical Center Human Research Protection Office IRB
reference AAAE8252, The Children’s Hospital of Philadelphia IRB reference 10–007816, Bos-
ton Children’s Hospital Office of Clinical Investigations IRB reference 05-02-028, Stanford
University Research Compliance Office IRB reference 31140). The Italian ethical requirements
for natural history studies mean that the Italian SMA Network was not provided with an IRB
number. All participants had given their explicit written informed consent to participate in the
site specific natural history studies. The evaluators conducting the RHS assessments were the
expert physiotherapists who developed the scale in addition to network physiotherapists who
were deemed competent to complete the RHS assessments following local training by the
expert physiotherapists.
Additional reliability and validity testing. Content validity of the RHS from a patient/
parent perspective in addition to preliminary inter and intra-rater reliability of the RHS in a
UK cohort of Physiotherapists has been established in concurrent studies which will be
reported separately in the future.
Revised Hammersmith Scale for spinal muscular atrophy
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Results
One hundred and thirty-eight patients with genetically confirmed chromosome 5q SMA clas-
sified with SMA type 2 or type 3 were evaluated using the RHS between March and September
2015 across the three national networks. Of the 138 patients 89 had type 2 and 49 had type 3,
of these 40 were type 3a and 9 were type 3b. Ambulation was defined as the ability to ambulate
without aids or orthotics over 10 metres, 65.3% (32/49) of patients with type 3 SMA were
ambulant (type 3a n = 24, median age 9 years 10 months; type 3b n = 8, median age 18 years 7
months). There was similar distribution across the sexes with 72 males and 66 females
assessed. The median age at assessment was 8 years 6 months (IQR 4 years 10 months to 12
years 4 months), the age range varied from 1 year 4 months to 51 years 7 months. With regards
orthopaedic interventions, 10.1% of patients had undergone spinal surgery (n = 14).
RHS content
The final RHS consisted of 36 items for very weak SMA 2 through to very strong SMA 3. With
regards scoring, 33 items were graded on an ordinal scale of 0, 1, 2 where 0 denotes the least
level of ability/function progressing to the highest level of ability to achieve a score of 2, the
remaining 3 items were scored 0, 1 where 0 is unable and 1 was able to achieve. The maximum
achievable score is 69. The scale was ordered to limit position change with items grouped
according to position tested for example sitting, supine, prone, standing etc., items within that
position progress from easier to more difficult i.e. items in supine move from crook/hook
lying to lie to sit. To avoid a ceiling effect, the RHS contains revised items from the NSAA
including two timed tests, and for the weaker end of the spectrum it also contains a revised
item from the CHOP INTEND. Two RHS items incorporated the equivalent WHO motor
milestone as their top score, item 16 cruising and item 18 walking. The current RHS scale pro-
forma can be found in the supplementary information (S1 Appendix). The proforma includes
the WHO motor milestones [39], which can be completed concurrently.
RHS pilot
The median score for the sample was 12 (IQR 6, 28), the lowest total score achieved on the
RHS was 0 (n = 1) and highest was 68 (n = 1). The RHS was able to discriminate between clini-
cally different groups (Table 1): SMA type (p< 0.001), ambulatory status (p< 0.001), SMA
type and current ambulatory status combined (p< 0.001) Fig 2a, highest current level of func-
tional ability as classified by WHO motor milestones (p< 0.001) Fig 2b, and whether a patient
had spinal surgery or not (p = 0.001). Distinctly different ranges of scores within these groups
was evident, Table 1, Fig 2. Gender did not have an influence on RHS scores (p = 0.986). The
RHS was significantly strongly correlated with the WHO motor milestones rs = 0.860,
p< 0.001. Table 1 contains further details on participant scores and demographics, and refer
to Fig 3 for the complete dataset scatterplot of RHS total scores versus age, stratified according
to SMA type with ambulant and non-ambulant patients distinguished.
Overall no relationship was observed between age and RHS score rs = 0.021 (p = 0.805), a
statistically significant inverse relationship with age was observed in the type 2 population rs =
-0.451 (p< 0.001), this was also observed to a lesser extent in the non-ambulant population
rs = -0.242 (p = 0.007), however both of these were deemed to be moderate to low correlations.
When stratifying the whole population into age groups of those< 5 years, 5–14.9 years
and 15 years no statistically significant differences in RHS score were observed across these
groups (p = 0.832). Further analysis of these age groups versus SMA type identified a pattern
of declining scores as age increased within type 2 SMA subjects (Kruskal Wallis p< 0.001),
Table 2. This was not statistically different in the type 3 population (SMA 3a p = 0.619, SMA
Revised Hammersmith Scale for spinal muscular atrophy
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3b p = 0.187), however an overall trend with declining scores as age increased was observed.
With regards ambulatory status a statistically significant pattern of declining scores as age
increased was observed in the non-ambulant population (p = 0.007), Table 2.
Psychometric properties of RHS
Of the 138 assessments there were 3 invalid results and one extreme score resulting in 134
assessments entered into the Rumm2030 software. Overall there was very good fit of the 36
items to the construct of motor performance in SMA, with no items with a fit residual outside
of ±2.5 (all items observed fit the predicted model well) and only one item, supine to side
lying (item 8), had a significant χ2 probability (p< 0.001; Table 3). A significant value is an
indicator that supine to side-lying is the item that fits the overall concept of motor ability in
SMA least well. Good reliability was demonstrated by a high Person Separation Index (PSI)
0.98 (Table 4). There were logical and hierarchical individual item scores for 27/36 items (Fig
4). The targeting of the items was excellent with minimal ceiling effect (Fig 5), however there
were fewer items measuring the ability of the weaker non-ambulant patients. Dependency
was noted between the items which assess both right and left and similar items such as rolling
Table 1. RHS Pilot sample demographics and discriminative/groups validity.
n Median Age years
(IQR)
Median RHS Score
(IQR)
Range Groups validity(p
value)
All participants 138 8.5 (4.8, 12.3) 12 (6, 28) 0–68
SMA Type 2 89 6.3 (4.2, 10.1) 7 (4, 12) 0–27 < 0.001*a
3a 40 9.3 (7.1, 12.7) 37 (26, 49) 2–67
3b 9 20 (16.3, 23.9) 57 (38, 61) 12–68
Ambulatory Status Non- Ambulant 106 7.4 (4.6, 11.2) 9 (4, 15) 0–41 < 0.001*b
Ambulant 32 9.8 (6.9, 17) 48 (39, 60) 24–68
SMA Type & Current Ambulatory
Status
2 89 6.3 (4.2, 10.1) 7 (4, 12) 0–27 < 0.001*a
3a non-ambulant 16 9.4 (7.6, 12.2) 23 (19, 31) 2–41
3b non-ambulant 1 22.1 12 12
3a ambulant 24 9.1 (6.9, 13.6) 47 (37, 54) 24–67
3b ambulant 8 18.6 (11.1, 36.0) 59 (43, 63) 31–68
WHO Groups—Current Functional
Status
131 7.9 (4.6, 11.8) 12 (5, 27) 0–68 < 0.001*a
No longer sits 16 11.1 (7.8, 15.6) 2 (1, 5) 0–8
Sits 71 6.3 (4.2, 9.8) 10 (5, 13) 2–26
Crawls 4 5.1 (3.3, 6.8) 25 (21, 25) 17–25
Stands with
assistance
2 4.2 (2.6, 5.8) 25 (23, 27) 23–27
Walks with
assistance
1 9.5 27 27
Stands alone 5 7.4 (5.9, 7.8) 26 (20, 34) 9–61
Walks alone 32 9.8 (6.9, 16.8) 46 (37, 58) 24–68
Gender Male 72 8.1 (4.9, 11.6) 12 (6, 29) 1–67 0.986b
Female 66 8.6 (4.8, 12.6) 12 (6, 28) 0–68
Spinal Surgery No 124 7.3 (4.6, 11.1) 13 (7, 33) 0–68 0.001*b
Yes 14 13.3 (11, 16.1) 3 (2, 6) 1–50
*Highly significant p 0.001
a Kruskal Wallis,
bMann-Whitney U Test
doi:10.1371/journal.pone.0172346.t001
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Fig 2. Discriminative/groups validity of the RHS. Median RHS total score (IQR and Range) versus a) SMA type combined with
current ambulatory status; b) Highest current level of motor ability according to WHO groups.
doi:10.1371/journal.pone.0172346.g002
Fig 3. Individual RHS total score data points versus age and SMA type for entire pilot cohort (n = 138). RHS total score versus age
and stratified according to SMA type, * ambulant and ˚ non-ambulant patients are distinguished, dotted lines represent floor (RHS total
score = 0) and ceiling effect (RHS total score = 69).
doi:10.1371/journal.pone.0172346.g003
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from prone to supine and supine to prone. Removing items which were repeated (removed
left side) did not influence the PSI (0.98) which remained virtually the same. Unidimensional-
ity was acceptable (t-test 7.3%, binomial test lower 95% confidence interval proportion, 0.05).
Disordered thresholds. Disordered thresholds are often highlighted during Rasch analy-
sis and denote items where the scoring grades are not distinctly different from one another,
therefore meaning that those items are not working from a psychometric perspective. Nine
disordered thresholds (Fig 4) were observed in the following items: sitting, hands to head in
sitting, lifting head from prone, four-point kneeling/crawling, cruising/supported stand,
standing, walking, high kneeling and climb step left. In all cases the middle score of ‘1’ was not
being detected as being distinctly different.
Timed test subgroup analysis: Items 19 and 25
Of the 49 type 3 patients, 13 with type 3a also completed the timed aspects of the 10 metre run/
walk (item 19) and 14 with type 3a completed the timed rise from floor (item 25). In both
groups age was not correlated with the overall RHS total score, Table 5 (timed 10 metre group
rs = -0.079 p = 0.797; timed rise group rs = -0.011, p = 0.971). A significant inverse linear rela-
tionship between RHS total score and timed tests was found (Table 5); 10 metre run rs = -0.912
strong correlation p< 0.001, rise from floor rs = -0.693 moderate correlation p< 0.001. Both
timed tests were moderately correlated with each other, however this did not achieve statistical
significance rs = 0.588 p = 0.074, Table 5. The ordinal scoring utilised in both item 19 and 25
enabled further discrimination within the timed tests by distinguishing between clinically dif-
ferent abilities p< 0.05 in all cases, Table 5.
Discussion
The original HFMSE has clear clinical utility in the assessment of SMA and is being success-
fully used in ongoing studies. Nevertheless its psychometric properties have demonstrated
some discontinuities. In addition, ongoing therapeutic developments highlight the need for a
scale which has the capacity to demonstrate improvement, and in this respect the HFMSE may
be more susceptible to ceiling effects in stronger patients following successful therapeutic
intervention. We have undertaken a comprehensive process to produce an SMA specific
motor performance rating scale which is robust from a psychometric perspective, clinically rel-
evant and with the capacity/sensitivity to demonstrate improvement.
We have established in an international multicentre study that the RHS is able to assess a
broad range of physical abilities across the spectrum, from weak SMA type 2 through to very
strong type 3. The scale therefore demonstrates face validity of the underpinning concept of
Table 2. Age stratification versus median RHS score (IQR).
n < 5 years n 5–14.9 years n  15 years Groups validity (p value)a
Total population 36 12 (7, 17) 78 11 (6, 27) 24 16 (3, 43) 0.832
SMA 2 31 10 (6, 13) 48 7 (5, 11) 10 2 (2, 3) < 0.001**
SMA 3a 4 43 (35, 49) 29 35 (25, 50) 7 33 (20, 47) 0.619
SMA 3b 1 68 1 61 7 47 (31, 60) 0.187
Non-ambulant 31 10 (6, 13) 62 9 (5, 20) 13 3 (2, 6) 0.007*
Ambulant 5 45 (41, 52) 16 51 (44, 63) 11 47 (33, 57) 0.463
*significant,
**highly significant,
aKruskal Wallis
doi:10.1371/journal.pone.0172346.t002
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Table 3. Individual item fit for RHS in order of difficulty.
Seq Item Location Fit Residual Chi Squared Chi squared probability
1 Sit -7.405 -0.035 0.658 0.7196
8 Supine to side lying -6.647 0.085 20.584 0.0000*
4 Crook lying -6.409 0.043 8.18 0.0167
2 Hands to head -4.453 -0.022 1.89 0.3887
9 Rolls supine to prone -3.909 -0.281 5.07 0.0793
11 Props on forearms -3.385 -0.422 1.211 0.5459
3 Sit to lie -3.247 -0.339 1.064 0.5875
13 Rolls prone to supine -3.104 -0.757 5.047 0.0802
5 R hip flexion -2.73 1.568 12.294 0.0021
6 L hip flexion -2.386 2.496 8.413 0.0149
10 Lifts head from prone -2.016 0.195 5.887 0.0527
12 Four point/ crawl -1.155 -0.278 0.442 0.8018
16 Cruise / supported stand -1.108 -0.933 1.517 0.4683
7 Lifts head supine -0.717 1.103 9.377 0.0092
14 Lie to sit -0.669 -0.686 0.645 0.7245
17 Standing -0.226 -0.529 0.8 0.6704
18 Walking 0.127 0.075 3.808 0.1490
22 High kneeling 0.564 -0.319 2.067 0.3557
26 Stand on R leg 1.263 -0.507 1.135 0.5669
24 High kneel to L half 1.306 -0.405 2.511 0.2850
23 High kneel to R half 1.328 -0.559 2.397 0.3017
27 Stand on L leg 1.436 -0.452 0.975 0.6142
15 Sit to stand 1.533 -1.015 4.634 0.0986
30 Climb stairs 2.357 -0.662 1.13 0.5682
21 Stand to sit on floor 2.477 -0.432 0.118 0.9426
33 Down box step R 2.549 -0.244 0.428 0.8076
31 Descend stairs 2.555 -0.301 0.828 0.6609
35 Down box step L 2.716 -0.235 0.514 0.7734
32 Climbs box step R 2.831 -0.254 0.632 0.7289
34 Climbs box step L 2.857 -0.217 0.815 0.6655
19 Runs 10 metres 3.401 -0.398 0.672 0.7145
20 Squat up and down 3.735 -0.478 0.912 0.6338
25 Rise from floor 3.828 -0.264 0.326 0.8495
36 Jumps forward 3.896 -0.125 0.105 0.9605
28 Hops R 4.401 -0.156 0.32 0.8593
29 Hops L 4.407 -0.157 0.32 0.8591
* significant χ2 probability p = 0.001
doi:10.1371/journal.pone.0172346.t003
Table 4. Overall properties of RHS using the Rasch measurement method.
Item Fit SD Person Fit SD PSI DF
RHS -0.164 0.658 -0.226 0.337 0.9753 72
PSI—Person separation index; DF—Degrees of freedom
doi:10.1371/journal.pone.0172346.t004
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interest and construct of the RHS. The widespread scatter of scores observed in the SMA 3a
range (Fig 3) is of particular interest because it demonstrates the ability of the scale to capture
the continuum from ambulant to non-ambulant, and it could be postulated that the converse
could also be true. This together with the lack of ceiling effect (68 was the maximum score
Fig 4. Rasch analysis: RHS 17.03.2015 threshold map for items in RHS in ranked order of difficulty. The
presence of horizontal bars indicates that for these items as an individual’s ability increases they would be more likely to
achieve a higher score and that this would increase systematically in a logical progression. They would first score 0, then
1 and then 2 as ability improves. The inverse is also true. Within each bar a number 1 represents a score of 0 on the
RHS, 2 represents a score of 1, and 3 represents a score of 2.
doi:10.1371/journal.pone.0172346.g004
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achieved n = 1) and inclusion of timed tests for type 3 patients highlights that the RHS pos-
sesses the capacity to demonstrate further improvement in both SMA types 2 and 3.
The RHS correlated strongly with the WHO motor milestones confirming the scale mea-
sures progressively more difficult motor abilities, therefore establishing concurrent validity of
the scale. The RHS demonstrated discriminative groups validity by statistically distinguishing
between clinically different groups: current WHO functional ability, SMA type, ambulatory
status, SMA type combined with current ambulatory status and whether patients underwent
surgery or not. Further longitudinal studies are required to investigate discriminant validity
with regards markers of SMA disease pathology for example SMN2 copy number and CMAP.
Content validity from a patient perspective and inter and intra-rater reliability has been
Fig 5. Rasch analysis: RHS 17.03.2015 person item threshold distribution. Targeting of the patient
sample (top) to individual items (bottom). The figure shows the targeting between the distribution of
person measurements (upper histogram) and the distribution of the item locations (lower histogram).
doi:10.1371/journal.pone.0172346.g005
Table 5. SMA Type 3 sub analysis: RHS timed tests (all SMA 3a).
Timed 10 m (n = 13) Timed Rise from floor (n = 14)
Median
(IQR)
Correlation with
timed test rs
(p value)a
Discriminative
Validity p valueb
Median (IQR) Correlation with timed
test rs (p value)a
Discriminative
Validity p valueb
Age (years) 9 (6.9, 11.9) 0.049 (0.873) Age (years) 9.2 (6.9,
11.9)
0.336 (0.240)
RHS Total
Score
51 (48, 59) -0.912 (< 0.001**) RHS Total Score 50 (39, 59) -0.693 (0.006*)
Item 19: 10
metre Run
(secs)
8.53 (5.62,
9.73)
-0.741 (0.004*) Item 25: Rise
from Floor (secs)
7.8 (4.03,
18.33)
-0.703 (0.005*)
Item 19 Score 0
(secs)
15.52 (9.73,
21.30)
0.035* Item 25 Score 0
(secs)
18.33 (15.57,
18.81)
0.039*
Item 19 Score 1
(secs)
8.53 (6.02,
9.44)
Item 25 Score 1
(secs)
5.18 (3.70,
7.80)
Item 19 Score 2
(secs)
4.48 (4.47,
4.50)
Item 25 Score 2
(secs)
3.58 (3.58,
3.58)
aSpearman’s Rho,
bKruskal Wallis,
*Significant p < 0.05,
**Highly significant p 0.001.
doi:10.1371/journal.pone.0172346.t005
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studied in the UK and is presented in parallel papers currently in preparation. Further interna-
tional inter and intra-rater reliability testing is planned.
Rasch analysis demonstrated that the RHS measures with a good degree of accuracy the
construct of motor performance in type 2 and 3 SMA. The strength of the RHS is the psycho-
metrically ordered scoring determined through the application of clinical sensibility. This has
resulted in increased items which sensitively capture a broader spectrum of abilities. The scor-
ing system worked well in 27/36 items, the remaining 9 items were classified as having disor-
dered thresholds whereby the middle score of 1 was not being picked up as being distinctly
different to a score of 0 or 2. The majority of disordered thresholds occurred in what could be
considered ‘transitional items’ relevant in specific SMA subtypes where a patient may be con-
sidered anecdotally as a ‘weaker type 2’, ‘strong type 2’, ‘weaker type 3’ or in the process of
transitioning from ambulant to non-ambulant. These subgroups were represented by a small
number of patients. This study used a cross-sectional sample to test the RHS, and it is possible
that these ‘transitional items’ may be more relevant in a longitudinal cohort to assess change
within individual subjects. Over time these items may, for example, capture the transient phys-
ical abilities observed during the progression from ambulant to non-ambulant or when losing
the ability to sit. It would be difficult to gather a sufficient sample of patients to demonstrate
this cross-sectionally, and whilst the transitional items represent a small proportion of patients,
the consensus of the experts was that there is definite clinical value in capturing this informa-
tion. Transitional items are also important when considering clinical trials. There may be
potential treatments for SMA which may demonstrate an improvement in the condition not
seen previously in the natural history, for example acquisition of skills progressing from non-
ambulant to ambulant. Therefore, despite the relative inconsistencies observed in the nine dis-
ordered thresholds, the expert panel recommended retention of these items with their current
scoring criteria due to their clinical utility and potential to more sensitively capture longitudi-
nal progression or potential improvement in SMA over time. Longitudinal changes at six and
twelve months are currently being investigated.
The relationship between age and RHS score was most apparent when looking at the strati-
fied age groups < 5 years, 5–14.9 years and 15 years in SMA 2 patients and non-ambulant
patients. These results are in keeping with those found by Mercuri et al., (2016) whereby the
influence of age on longitudinal HFMSE functional scores was greatest in non-ambulant
patients suggesting a different trajectory of progression when compared with ambulant
patients at both baseline and 12 months [18].
Since the introduction of the classification of the three classical types of SMA observed in
infancy/childhood there has been discussion as to whether this approach is too rigid given the
wide spectrum of physical ability observed within each type [41–44]. The original HFMS
paper proposed criteria to aid sub classifying SMA type 2 into ten further decimalised catego-
ries based upon the score achieved on the HFMS, although used anecdotally in highly experi-
enced clinicians this has not to date been adopted by the SMA community as a whole [10].
The last few years has seen a concerted effort to improve the descriptors for SMA types 0, 1
and 3 with further sub-division of type often noted with a letter i.e. SMA 1b, 3a etc. [9, 10, 41].
In this study the WHO motor milestones were used to identify the current level of function in
SMA patients, this may be different to the highest level of ability ever achieved required for
classifying SMA type, for example a patient who was classified as type 2 who has lost the ability
to sit. The WHO motor milestones are more detailed functional descriptors in comparison to
SMA type or current ambulatory status, but are not as comprehensive in describing the cur-
rent functional abilities as the RHS itself. Using the WHO and RHS together highlighted fur-
ther sub-populations and distinct ranges of functional scores for certain abilities, for example
those who are no longer able to sit scored between 0 and 8 on the RHS, those who crawled
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score between 17 and 24, and those who walked scored between 24 and 68. These, as prelimi-
nary findings of a new scale, require further validation in large longitudinal multi-centric stud-
ies. Revisiting use of a more sensitive classification by using the WHO motor milestones and
the RHS together may be a useful strategy to aid understanding and future stratification of
‘within type’ SMA natural history trajectories. This may lead to the development of more
refined trial inclusion/exclusion criteria. A recommendation following this study would be to
expand the qualifiers to include the ability to ambulate independently (thus be qualified as
ambulant) without orthotics or aids over 10 metres, this information could be somewhat
extrapolated from RHS item 19.
Recently the need for items which are able to sensitively discriminate between groups of
patients has become even more pertinent [45, 46]. An increased utility of the RHS in compari-
son with other outcome measures currently used in clinical trials is the inclusion of timed tests
and discriminative items for type 3 patients. This study identified that the individual item ordi-
nal scores for the timed test items 19 and 25 can discriminate between clinically different
groups in SMA type 3a patients in the times they achieved. Although these milder individuals
only represented a small number of patients, this highlights a further discriminative capability
of the RHS which is advantageous and warrants further investigation.
In this study the impact of contractures, scoliosis, height and weight on the functional score
was not investigated, further studies are required to investigate the extent to which these fac-
tors may have a confounding impact on the RHS. Further work is required regarding the
potential for the RHS to act as a transitional scale for stronger type 1 patients when the CHOP
INTEND scale is no longer appropriate and a floor effect exists on the HFMSE, this is particu-
larly pertinent in light of the ongoing clinical trials in this patient population.
Conclusion
This study has described in comprehensive detail the content, construct, concurrent and dis-
criminative groups validity properties of the RHS scale in a large international cohort of
patients with SMA types 2 and 3. The strength of the RHS is that it has been developed to
address the minor discontinuities observed in the original HFMSE and has expanded the abil-
ity to monitor changes at the two extremes of the scale which is particularly relevant for trans-
lational research applications. It has been prospectively designed using rigorous clinical
reasoning and modern psychometrics, therefore complementing existing constructs making it
a valid instrument for clinical trials.
Use of the RHS in combination with the WHO motor milestones may enable more sensitive
description of SMA phenotype and trajectories, which may in turn, facilitate more accurate
sub-type analysis. Our findings also suggest that the incorporation of timed tests may enable
further discrimination within type 3 patients. Further work is needed to establish how the
RHS should be used in conjunction with the CHOP INTEND for very weak infants and to
establish the relationship with Upper Limb Modules or person reported outcome measures.
Work is underway to investigate the clinical meaningfulness of the nine items with disordered
thresholds, and longitudinal investigation of the RHS measurement properties over six and
twelve months. With regards psychometric properties it is anticipated that a linearised version
of the scale will be developed, which will be underpinned by the parallel work undertaken to
address content validity from a patient perspective.
One of the key strengths of the RHS is the rigorous iterative process employed during its
development, expanding upon an already well-developed scale, involving use of expert panels,
psychometric analysis and several international pilots, resulting in construction of a robust
SMA specific clinical outcome assessment tool. As the results demonstrate, the RHS is a
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versatile tool able to capture a broad range of abilities across the spectrum of SMA, from
young children through to adults, and in varying stages of the disease course.
Supporting information
S1 Appendix. RHS Testing proforma version 17.03.2015 including WHO motor mile-
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